Related Experiment Videos

Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower

A J Garber1

  • 1Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA.

Diabetes, Obesity & Metabolism
|February 28, 2001
PubMed

Insights

Patients with type 2 diabetes and coronary heart disease (CHD) benefit from aggressive lipid-lowering therapy. Specific statins like pravastatin and simvastatin, and gemfibrozil, reduce cardiovascular events in these high-risk individuals.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes significantly elevates coronary heart disease (CHD) risk, often exacerbated by abnormal lipid profiles.
  • Insulin resistance, hyperinsulinaemia, hypertension, and elevated fibrinogen/plasminogen activator inhibitor contribute to cardiovascular risk, not fully managed by glycemic control.
  • Aggressive lipid-lowering therapy has demonstrated substantial reductions in CHD risk among diabetic patients in major trials.

Purpose of the Study:

  • To evaluate the efficacy of lipid-lowering therapies in reducing cardiovascular events in patients with type 2 diabetes and CHD.
  • To compare the effectiveness and safety profiles of different lipid-lowering agents, including gemfibrozil, pravastatin, and simvastatin.

Main Methods:

  • Review of large interventional trials assessing lipid-lowering therapy in diabetic patients with CHD.
  • Analysis of data on fatal and non-fatal CHD events associated with specific lipid-lowering drugs.

Main Results:

  • Gemfibrozil effectively reduced CHD events in diabetic patients with CHD, low HDL, and normal LDL.
  • Pravastatin and simvastatin are the only HMG-CoA reductase inhibitors proven to decrease fatal and non-fatal CHD events in diabetic patients with CHD.
  • Pravastatin exhibits a lower potential for drug-drug interactions, suggesting enhanced safety, especially in combination therapy for mixed dyslipidemias.

Conclusions:

  • Aggressive lipid-lowering is crucial for managing cardiovascular risk in type 2 diabetes patients with CHD.
  • Pravastatin and simvastatin offer proven benefits for CHD event reduction in this population.
  • Pravastatin's safety profile may favor its use in combination therapies for comprehensive cardiovascular risk management.

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...